Skip to main content
Premium Trial:

Request an Annual Quote

SomaLogic Collaborating With UH Cleveland Medical Center on Use of SomaSignal Tests

NEW YORK – SomaLogic said Monday that it has entered a collaboration with University Hospitals Cleveland Medical Center to evaluate the impact of its SomaSignal tests on managing diabetic patients at high risk of cardiovascular disease.

The parties will use the test in clinical trials and development projects with the aim of identifying diabetic patients with an elevated risk for cardiovascular disease and tracking the effectiveness of treatments used for these patients, including therapies such as SGLT-2 inhibitors and GLP-1 agonists.

The collaboration adds to previously announced agreements around SomaSignal with organizations including Emory University, Intermountain Healthcare, CommonSpirit Health and UCHealth.

The SomaSignal tests use SomaLogic's aptamer-based affinity reagents called Somamers to measure proteins in patient samples. It currently offers 12 tests as laboratory-developed tests for indications including risk of major cardiovascular events in patients with and without known heart disease and the presence of excess liver fat.

"This partnership with SomaLogic consolidates the vision of UH and UH Harrington Heart & Vascular Institute to be a leader in precision medicine platforms to guide decision making," Sanjay Rajagopalan, chief academic and scientific officer for the UH Harrington Heart & Vascular Institute and Herman Hellerstein professor of cardiovascular medicine, said in a statement. "Given the breadth of expertise in precision medicine tools at UH, particularly in the imaging space, that are readily available to clinicians, we were a natural choice to extend these approaches to emerging next-generation proteomic methods."

Financial and other terms of the deal were not disclosed.